BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duan CL, Hou GH, Liu YP, Liang T, Song J, Han JK, Zhang C. Tumor vascular homing endgolin-targeted radioimmunotherapy in hepatocellular carcinoma. Tumour Biol 2014;35:12205-15. [PMID: 25164610 DOI: 10.1007/s13277-014-2529-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Jeng KS, Sheen IS, Lin SS, Leu CM, Chang CF. The Role of Endoglin in Hepatocellular Carcinoma. Int J Mol Sci 2021;22:3208. [PMID: 33809908 DOI: 10.3390/ijms22063208] [Reference Citation Analysis]
2 Barriuso B, Antolín P, Arias FJ, Girotti A, Jiménez P, Cordoba-Diaz M, Cordoba-Diaz D, Girbés T. Anti-Human Endoglin (hCD105) Immunotoxin-Containing Recombinant Single Chain Ribosome-Inactivating Protein Musarmin 1. Toxins (Basel) 2016;8:E184. [PMID: 27294959 DOI: 10.3390/toxins8060184] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 Duan C, Li Y, Yang W, Zhang C. Combination of 131 I-anti-endoglin monoclonal antibody and 5-fluorouracil may be a promising combined-modality radioimmunotherapy strategy for the treatment of hepatocellular carcinoma. Biotechnology & Biotechnological Equipment 2018;32:974-81. [DOI: 10.1080/13102818.2018.1475254] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Kasprzak A, Adamek A. Role of Endoglin (CD105) in the Progression of Hepatocellular Carcinoma and Anti-Angiogenic Therapy. Int J Mol Sci. 2018;19. [PMID: 30563158 DOI: 10.3390/ijms19123887] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
5 Zhu ZX, Liao MH, Wang XX, Huang JW. Transcatheter Arterial Chemoembolization Plus 131I-Labelled Metuximab versus Transcatheter Arterial Chemoembolization Alone in Intermediate/Advanced Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Korean J Radiol 2016;17:882-92. [PMID: 27833404 DOI: 10.3348/kjr.2016.17.6.882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]